Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.

Bariatric surgery improves BP control in obese, hypertensive patients

29 Aug 2020

Roux-en-Y gastric bypass (RYGB) results in better midterm blood pressure (BP) control and hypertension remission, requiring fewer medications in obese and hypertensive patients, a study has shown.

The investigators randomly assigned 100 patients (mean body mass index [BMI], 36.9 kg/m2; 76 percent female) with hypertension receiving at least two medications at maximum doses or more than two medications at moderate doses and with BMI between 30.0 and 39.9 kg/m2 to either RYGB plus medical therapy (MT) or MT alone.

Of the randomized participants, 88 percent from the RYGB group and 80 percent from the MT group completed follow-up. Seventy-three percent of patients from the RYGB group achieved the primary outcome of at least a 30-percent reduction in total number of antihypertensive medications while maintaining BP <140/90 mm Hg at 3 years compared with just 11 percent from the MT group (relative risk, 6.52, 95 percent confidence interval, 2.50–17.03; p<0.001).

In addition, 35 percent and 31 percent from the RYGB group compared with 2 percent and 0 percent from the MT group achieved BP <140/90 mm Hg and <130/80 mm Hg without medications, respectively.

At 3 years, the median number of medications was one (interquartile range [IQR], 0–2) in the RYGB group and three (IQR, 2.8–4) in the MT group (p<0.001). Total weight loss was 27.8 percent in the RYGB cohort and –0.1 percent in the MT cohort. Finally, 13 patients in the RYGB group developed hypovitaminosis B12 and two required reoperation.

This study was limited by its single-centre, nonblinded design.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
Pearl Toh, 12 Sep 2020
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.